Financial Survey: Aadi Bioscience (NASDAQ:AADI) and Oncobiologics (NASDAQ:OTLK)

Oncobiologics (NASDAQ:OTLK) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Analyst Recommendations

This is a summary of current recommendations for Oncobiologics and Aadi Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	4	2	0	2.14
Aadi Bioscience	0	0	0	0	0.00

Oncobiologics presently has a consensus price target of $4.65, indicating a potential upside of 618.48%. Given Oncobiologics’ stronger consensus rating and higher probable upside, analysts clearly believe Oncobiologics is more favorable than Aadi Bioscience.

Volatility & Risk

Oncobiologics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Profitability

This table compares Oncobiologics and Aadi Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Insider & Institutional Ownership

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Oncobiologics and Aadi Bioscience”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35 million	71.24	-$62.42 million	($0.77)	-0.84
Aadi Bioscience	$25.07 million	4.76	-$65.76 million	($2.35)	-2.06

Oncobiologics has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Summary

Oncobiologics beats Aadi Bioscience on 10 of the 14 factors compared between the two stocks.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Aadi Bioscience

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.